Contract Manufacturing, Biopharmaceutical Production

Rentschler Biopharma Launches New LV Vector Manufacturing Toolbox

September 04, 2024

Rentschler Biopharma now offers a new lentiviral vector manufacturing toolbox at its site in Stevenage, UK.

Leveraging Bioanalytical Studies Advancements

September 04, 2024

As the field of bioanalytical testing evolves, it is important for drug developers to stay at the forefront of the advancements to ensure they remain competitive.

A Look at the Outsourcing Landscape for mRNA (BIO 2024)

August 23, 2024

Christian Cobaugh, CEO and founder of Vernal Biosciences, considers the outsourcing landscape for mRNA production.

Pluri’s CDMO Business to Manufacture Cell Therapy Candidates from Kadimastem

July 19, 2024

Pluri’s newly launched CDMO business will manufacture two novel cell therapy product candidates for Kadimastem.

AGC Biologics and BioConnection Team Up on Biopharma Drug Development and Manufacturing

May 24, 2024

Under this partnership, AGC Biologics and BioConnection will provide development and manufacturing capabilities for biopharmaceutical drug substance and drug product.

Merck KGaA Set to Acquire Mirus Bio in $600 Million Deal

May 23, 2024

The Mirus Bio acquisition will boost Merck KGaA’s viral vector manufacturing services.

Polysorbates: Part(icle) of the Problem?

May 04, 2024

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

Ferring Pharmaceuticals and SK pharmteco Form Gene Therapy Manufacturing Pact

April 26, 2024

Contract manufacturer SK pharmteco will manufacture as well as conduct testing and release of Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy for bladder cancer.

Lonza Set to Manufacture Acumen Pharmaceuticals’ mAb for Alzheimer’s Disease

April 04, 2024

Lonza has made a deal with Acumen Pharmaceuticals to manufacture sabirnetug, a mAb that will soon be entering Phase II development for treating Alzheimer’s disease.

FDA Approves First Gene Therapy for Pediatric MLD from Orchard Therapeutics, and AGC Biologics Tapped to Manufacture It

March 19, 2024

Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) marks the first gene therapy approved in the US for treating children with metachromatic leukodystrophy.